9:55 AM · 10 October 2024

GlaxoSmithKline surges 5% on Zantac settlement deal in the US

Shares of British pharmaceutical giant, GlaxoSmithKline (GSK.US) more than 5% today amid $2.2 billion settlement deal in US Zantac lawsuits, caused by 'cancer-casuing' concerns. The deal will resolve 93% (almost 80,000) of US lawsuits. The company will recognize this loss in Q3 results, this year. All the settlements are expected to be implemented by the end of the first half of 2025. GSK confirmed also another $70 million paid to resolve the Zantac so-called qui tam complaint previously filed by Valisure. This agreement is pending final approval from the Department of Justice. Investors positively react to this news, improving 'uncertainty' about Zantac case.

 

Source: xStation5

 
 

 

9 July 2026, 10:52 AM

Market Wrap: Capital Flows Back into Tech; ASML Rises 2.5%🚀

9 July 2026, 8:47 AM

US100 rebounds 1% 🔼SK hynix attracts record demand ahead of Nasdaq debut.

9 July 2026, 8:39 AM

Does Iran actually want a “deal”? Trump shifts his narrative on Iran and Spain 💡

9 July 2026, 7:50 AM

Economic calendar: ECB minutes, US jobless claims and PepsiCo earnings in focus

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits